Ariad Pharm announced that Pharmacovigilance Risk Assessment Committee of EMA concluded review of Iclusig and has recommended that Iclusig continue to be used in Europe in accordance with its already approved indications
Fwd:>>> ARIA - Moves up on call activity - Oct 4.5 calls traded 3K contracts
PRAC recommends no change to approved indication in Europe
Fwd:>>> ARIA - Moves up on call activity - Oct 4.5 calls traded 3K contracts
From: LAURENT CHEKROUN () At: Oct 9 2014 17:13:59
To: LAURENT CHEKROUN ()
Subject: Fwd:>>> ARIA - Moves up on call activity - Oct 4.5 calls traded 3K contracts
Subject: Fwd:>>> ARIA - Moves up on call activity - Oct 4.5 calls traded 3K contracts
Moves up on call activity - Oct 4.5 calls traded 3K contracts{ARIA US Equity GIP<Go>}